Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals.
Infectious Diseases Department, University Hospital, Montpellier, Montpellier, France.
Christina
C
Psomas
Jean-Philippe
JP
Lavigne
Claudine
C
Barbuat
Selma
S
Trabelsi
Jade
J
Ghosn
Caroline
C
Lascoux-Combe
Philippe
P
Flandre
Lise
L
Cuzin
Jacques
J
Reynes
Brigitte
B
Autran
Pierre
P
Corbeau
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D003510:Cyclohexanes / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load / Q000187:drug effects*
D003510:Cyclohexanes; D014230:Triazoles